AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
AtaiBeckley Inc. (ATAI)
US:NASDAQ Investor Relations:
ir.atai.net.cn
Company Research
Source: GlobeNewswire
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End-of-Phase 2 meeting with the U.S. Food and Drug AdministrationOn-track for VLS-01 Phase 2 Elumina trial topline data readout anticipated in H2 2026Exploratory Phase 2a trial of EMP-01 in Social Anxiety Disorder met its primary safety and tolerability objective and demonstrated clinically meaningful improvements across key efficacy measuresCash runway through the planned early-2029 topline readouts from both Phase 3 pivotal studiesVirtual Investor Day scheduled for March 6, 2026 NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced fourth quarter and full year 2025 financial results and provided key regulatory, clinical and
Show less
Read more
Impact Snapshot
Event Time:
ATAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATAI alerts
High impacting AtaiBeckley Inc. news events
Weekly update
A roundup of the hottest topics
ATAI
News
- AtaiBeckley reports 2025 results as it eyes Q2 start for Phase 3 depression trial [Yahoo! Finance]Yahoo! Finance
- AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update [Yahoo! Finance]Yahoo! Finance
- Europe's VC gender gap isn't closing, even with more women writing checks [Yahoo! Finance]Yahoo! Finance
- AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant DepressionGlobeNewswire
- Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS TreatmentsPR Newswire
ATAI
Earnings
- 11/12/25 - Miss
ATAI
Sec Filings
- 2/26/26 - Form 144
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- ATAI's page on the SEC website